# Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

> **NCT01953926** · PHASE2 · TERMINATED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 582 (actual)

## Conditions studied

- Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

## Interventions

- **DRUG:** Neratinib
- **DRUG:** Fulvestrant
- **DRUG:** Trastuzumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01953926
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09-30
- **Primary completion:** 2023-01-02
- **Final completion:** 2023-01-02
- **Target enrollment:** 582 (ACTUAL)
- **Why stopped:** The study was terminated to align with the sponsor's current development plans for neratinib. The decision was not based on any new efficacy or safety data for neratinib.
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01953926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01953926, "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01953926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*